Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

62
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

111
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
111
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Description Of Baseline Quality Of Life In Patients Diagnosed With Metastatic Renal Cell Carcinoma

Description of Baseline Quality of Life in Patients Diagnosed with Metastatic Renal Cell Carcinoma

Guillermo Lendínez-Cano1,2, Carmen Belén Congregado Ruíz1,2, Miguel Ángel Gómez Luque1

  • 1Oncologic Urology Unit, Urology and Nephrology Department, University Hospital Virgen del Rocío, Seville, Spain.

Urologia Internationalis
|September 5, 2024

Related Experiment Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

View abstract on PubMed

Summary
This summary is machine-generated.

Metastatic renal cancer patients experience significant quality of life decline, particularly fatigue and worry. Real-world patient outcomes suggest a worse quality of life than observed in clinical trials.

Area of Science:

  • Oncology
  • Patient-Reported Outcomes
  • Quality of Life Research

Background:

  • Renal cancer (RC) often presents symptomatically at advanced stages, impacting survival rates.
  • Metastatic renal cancer (mRC) has a low 5-year survival rate.
  • Health-related quality of life (HRQoL) via patient-reported outcomes (PROs) is crucial for understanding patient experience and guiding treatment.

Purpose of the Study:

  • To analyze the baseline health-related quality of life (HRQoL) of patients with metastatic renal cancer (mRC).
  • To assess the impact of mRC on patients awaiting systemic treatment using the NCCN-FKSI 19 questionnaire.
  • To understand the patient-reported outcomes in a real-world clinical setting.

Main Methods:

  • Analysis of 78 consecutive mRC patients treated between September 2012 and September 2019.
Keywords:
FKSIMetastatic renal cell carcinomaPatient-reported outcomesQuality of life

Related Experiment Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
  • Description and analysis of baseline NCCN-FKSI 19 questionnaire responses prior to systemic treatment initiation.
  • Evaluation of patient-reported outcomes regarding quality of life, fatigue, worry, and rest.

    • Main Results:

    • Over 60% of patients reported fatigue or lack of energy.
    • 60.8% of patients expressed significant worry about disease progression.
    • Nearly 27% of patients were dissatisfied with their current quality of life.

    Conclusions:

    • Patients with mRC demonstrate a notable decline in quality of life, characterized by asthenia and disease-related anxiety.
    • The quality of life reported by real-world mRC patients appears to be poorer than that of patients in clinical trials.
    • HRQoL assessment is vital for managing mRC patients and improving clinical decision-making.